IN VIVO Execs On The Move, June 2014
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
You may also be interested in...
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
Avalon Healthcare appoints two new directors; Lantheus Holdings appoints new chief accounting officer; and more.
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.